Trop2 antibodies

A bi-valent or multi-valent antibody wherein said antibody comprises:

• an anti-Trop 2 antibody or binding fragment thereof, wherein the antibody comprises:
• a. a heavy chain variable domain (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, or 132;
• and
• b. a VH CDR2 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133;
• and
• c. a VH CDR3 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, 124, 134;
• and
• d. a light chain variable domain (VL) CDR1 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, or 137;
• and
• e. a VL CDR2 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118, 128, or 138;
• and
• f. a VL CDR3 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, or 139;
• and
• a second antibody, antigen-binding of the second antibody or fragment thereof;
• a target-binding protein, a cytokine;
• a lectin;
• or a toxin.

A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-Trop 2 antibody or binding fragment thereof, wherein the antibody comprises:

• a. a heavy chain variable domain (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, or 132;
• and
• b. a VH CDR2 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133;
• and
• c. a VH CDR3 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, 124, 134;
• and
• d. a light chain variable domain (VL) CDR1 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, or 137;
• and
• e. a VL CDR2 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118, 128, or 138;
• and
• a VL CDR3 comprising the amino acid sequence of any one of the following SEQ ID NOs:
• 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, or 139.

A nucleic acid encoding an antibody, binding fragment thereof, bivalent, or multivalent nucleic acid sequence comprising:

• a. a VH is encoded by a nucleic acid sequence comprising of any one of the following SEQ ID NOs:
• 5, 15, 25, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 135, 157, 159, 161, or 163, and
• b. a VL is encoded by a nucleic acid sequence comprising of any one of the following SEQ ID NOs:
• 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 165, 167, or 169;
• or
• c. an antibody encoded by a nucleic acid sequence of SEQ ID NOS:
• 187 and 189, or 191 and 193;
• or
• d. a bispecific antibody encoded by a nucleic acid sequence of SEQ ID NOS:
• 175 and 177, 179 and 181, 183 and 185, 187 and 189, or 191 and 193, or combinations thereof.